豪悦護理(605009.SH):温州甌泰擬減持不超3%股份
格隆匯12月24日丨豪悦護理(605009.SH)公佈, 2021年12月24日,公司收到温州甌泰出具的《温州甌泰投資企業(有限合夥)關於持股5%以下股東減持股份計劃的吿知函》,温州甌泰因自身運營需求,計劃通過大宗交易方式減持,本次累計減持不超過479.51萬股,即不超過公司總股本的3.00%。
其中,通過大宗交易方式減持的,將於本減持計劃披露之日起3個交易日後的3個月內進行,減持期間為2021年12月30日至2022年3月29日,且在任意連續60日內,減持股份的總數不超過3,196,766股,即不超過公司股份總數的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.